NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Purchases $46,800.00 in Stock

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Jonathan C. Javitt bought 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were bought at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the transaction, the chairman now directly owns 84,634 shares of the company’s stock, valued at $99,021.78. This trade represents a 89.62 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $1.52 on Friday. The firm has a fifty day moving average of $1.28 and a 200-day moving average of $1.88. The stock has a market cap of $18.38 million, a price-to-earnings ratio of -0.71 and a beta of 1.25. NRx Pharmaceuticals, Inc. has a 52-week low of $1.10 and a 52-week high of $7.33.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

Wall Street Analysts Forecast Growth

NRXP has been the topic of several research analyst reports. EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st. Ascendiant Capital Markets boosted their price target on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, November 25th.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.